Mood and Behaviors of Adolescents With Depression in a Longitudinal Study Before and During the COVID-19 Pandemic.


Journal

Journal of the American Academy of Child and Adolescent Psychiatry
ISSN: 1527-5418
Titre abrégé: J Am Acad Child Adolesc Psychiatry
Pays: United States
ID NLM: 8704565

Informations de publication

Date de publication:
11 2022
Historique:
received: 14 01 2022
revised: 02 03 2022
accepted: 01 04 2022
pubmed: 23 4 2022
medline: 1 11 2022
entrez: 22 4 2022
Statut: ppublish

Résumé

To investigate whether, compared to pre-pandemic levels, depressive and anxiety symptoms in adolescents with depression increased during the pandemic. We used data from National Institute of Mental Health Characterization and Treatment of Depression (NIMH CAT-D) cohort, a longitudinal case-control study that started pre-pandemic. Most of the participants are from the states of Maryland and Virginia in the United States. We compared depressive symptoms (1,820 measurements; 519 measurements pre-pandemic and 1,302 during the pandemic) and anxiety symptoms (1,800 measurements; 508 measurements pre-pandemic and 1,292 ratings during the pandemic) of 166 adolescents (109 girls, 96 adolescents with depression) before and during the pandemic. Data were collected during yearly clinical visits, interim 4-month follow-up visits, inpatient stays, and weekly outpatient sessions, with additional data collection during the pandemic. Pre-pandemic, healthy volunteers (HVs) had a median of 1 depressive and anxiety rating (range, 1-3), and adolescents with depression had a median of 2 ratings (anxiety rating range, 1-25; depressive rating range, 1-26). During the pandemic, HVs had a median of 8 anxiety ratings and 9 depressive ratings (range, 1-13), and adolescents with depression had a median of 7 anxiety and depressive ratings (range, 1-29). We also analyzed adolescent- and parent-reported behaviors in the CoRonavIruS Health Impact Survey (CRISIS), totaling 920 self-reported measures for 164 adolescents (112 girls, 92 adolescents with depression). HVs had a median of 7 surveys (range, 1-8), and adolescents with depression had a median of 5 surveys (range, 1-8). Pre-pandemic, adolescents with depression had a mean depressive score of 11.16 (95% CI = 10.10, 12.22) and HVs had a mean depressive score of 1.76 (95% CI = 0.40, 3.13), a difference of 9.40 points (95% CI = 7.78, 11.01). During the pandemic, this difference decreased by 22.6% (2.05 points, 95% CI = 0.71, 3.40, p = .003) due to 0.89 points decrease in severity of scores in adolescents with depression (95% CI = 0.08, 1.70, p = .032) and 1.16 points increase in HVs' depressive symptoms (95% CI = 0.10, 2.23, p = .032). Compared to their pre-pandemic levels, adolescents with depression reported overall lower anxiety symptoms during the pandemic. Parent-on-child reports also were consistent with these results. Contrary to our hypothesis, we found that both depressive and anxiety symptoms were lower for adolescents with depression during the pandemic compared to before. In contrast, the depression scores for the HVs were higher during the pandemic relative to their pre-pandemic ratings; these scores remained much lower than those of adolescents with depression. Characterization and Treatment of Adolescent Depression; https://clinicaltrials.gov/; NCT03388606.

Identifiants

pubmed: 35452785
pii: S0890-8567(22)00195-2
doi: 10.1016/j.jaac.2022.04.004
pmc: PMC9015953
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03388606']

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1341-1350

Subventions

Organisme : Intramural NIH HHS
ID : ZIA MH002957
Pays : United States

Informations de copyright

Copyright © 2021 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Auteurs

Neda Sadeghi (N)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland.

Payton Q Fors (PQ)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland.

Lillian Eisner (L)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Emotion and Development Branch, National Institute of Mental Health, Bethesda, Maryland.

Jeremy Taigman (J)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Emotion and Development Branch, National Institute of Mental Health, Bethesda, Maryland.

Karen Qi (K)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Emotion and Development Branch, National Institute of Mental Health, Bethesda, Maryland.

Lisa S Gorham (LS)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Medical Scientist Training Program, Washington University in St. Louis School of Medicine, St. Louis, Missouri.

Christopher C Camp (CC)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Interdepartmental Neuroscience Program, Yale University, New Haven, Connecticut.

Georgia O'Callaghan (G)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland.

Diana Rodriguez (D)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Emotion and Development Branch, National Institute of Mental Health, Bethesda, Maryland.

Jerry McGuire (J)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Bethesda, Maryland.

Erin M Garth (EM)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Autoimmune Brain Disorders Program, National Institute of Mental Health, Bethesda, Maryland.

Chana Engel (C)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Emotion and Development Branch, National Institute of Mental Health, Bethesda, Maryland.

Mollie Davis (M)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Emotion and Development Branch, National Institute of Mental Health, Bethesda, Maryland.

Kenneth E Towbin (KE)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; Emotion and Development Branch, National Institute of Mental Health, Bethesda, Maryland.

Argyris Stringaris (A)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland; National and Kapodistrain University of Athens, Greece, and University College London, United Kingdom. Electronic address: a.stringaris@ucl.ac.uk.

Dylan M Nielson (DM)

Section of Clinical and Computational Psychiatry, National Institute of Mental Health, Bethesda, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH